Sun Pharmaceutical Industries Limited
Momentum (82/100) does the heavy lifting; valuation (45/100) is the drag.
Fair valueSun Pharmaceutical Industries Limited earns a Buy from StocksWizard, with a blended score of 67/100. At ₹1,989.9 it trades above our blended DCF and relative-multiples fair value of ₹1,798.95, about 10% downside to that estimate — we read it as fairly valued. On 39.2x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹1,989.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹2,047.35 implies about 3% upside across 34 analysts. It clears 9 of 13 investability checks, with durability 77, valuation 56 and momentum 82 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,439.16.
Analyst views
1-year price
EOD · 2026-07-2952-week range
+0.00% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy67Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 14.7%
- Pass: Low debt (D/E < 0.5): 0.06x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 13%
- Pass: Earnings growing: 26%
- Pass: Net margin ≥ 10%: 19.6%
- Pass: Current ratio > 1.5: 2.82
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 12.57
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter55.6%
- Institutions31.5%
- Public & other12.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (19.6%).
- Trading near its 52-week high.
- Financially solid — Altman Z 12.57.
Opportunities
- Earnings growing (26% YoY).
- Revenue growing (13% YoY).
Bear case
Weaknesses
- Weak Piotroski score (3/9).
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical develops, manufactures, and markets branded and generic pharmaceutical formulations along with active pharmaceutical ingredients across India, the United States, and international markets. The company operates across multiple therapeutic areas including neuropsychiatry, cardiology, diabetes, gastroenterology, pain management, gynecology, ophthalmology, urology, dermatology, respiratory conditions, anti-infectives, and oncology.
Sun Pharmaceutical Industries Limited — frequently asked questions
Is Sun Pharmaceutical Industries Limited a buy, hold or sell?
StocksWizard currently rates Sun Pharmaceutical Industries Limited (SUNPHARMA) a Buy, based on a blended score of 67/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Sun Pharmaceutical Industries Limited's fair value?
Our blended DCF and relative-valuation model estimates Sun Pharmaceutical Industries Limited's fair value at about ₹1,798.95, versus a current price of ₹1,989.9 — roughly 10% downside. On that basis the stock looks fairly valued.
Is Sun Pharmaceutical Industries Limited financially healthy?
Sun Pharmaceutical Industries Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Sun Pharmaceutical Industries Limited's share price performed?
Sun Pharmaceutical Industries Limited is up 10% over three months, and last traded at ₹1,989.9. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.